Inscrição YC de BillionToOne

Summer 2017Public

BillionToOne passou pela Y Combinator no batch Summer 2017 como uma empresa Healthcare. Abaixo: o que a empresa faz, quem a fundou e sua inscrição para a YC, reconstruída pergunta por pergunta no formulário real da YC.

Batch YC: Summer 2017
Indústria: HealthcareDiagnostics
Tamanho da equipe: 300
Status: Public
Lançada: 2016

Fundadores

Oguzhan AtayFounder
David TsaoFounder/CTO

O que BillionToOne faz

BillionToOne has developed a DNA molecular counter that increases the cell-free DNA diagnostics resolution by over 1,000 fold, which unlocks transformative improvements in prenatal screening and liquid biopsy for cancers. Unity Screen, BillionToOne's commercially available non-invasive prenatal test (NIPT), is the only NIPT that can assess fetal risk for both recessive conditions and aneuploidies from maternal blood. UNITY Screen continues to grow exponentially and is on its path to becoming the next standard-of-care, with an increasing number of publications showing its accuracy and advantages over other screening methods. We have also recently used our molecular counting technology to develop liquid biopsy tests, which have the potential to completely transform oncology care.

Inscrição YC de BillionToOne, reconstruída

Inscrição Y Combinator

BillionToOne, lote Summer 2017. As verdadeiras perguntas do formulário, respondidas com dados públicos.

Founders2
Company7
Progress7
Idea4
Equity3
Curious2
Batch Preference1

Company

Company name

BillionToOne

Describe what your company does in 50 characters or less.

The genetic testing platform detecting and measuring disease.

What is your company going to make? Please describe your product and what it does or will do.

We have built a DNA molecular counter that improves the resolution of cell-free DNA diagnostics by over a thousand times. Our main product, UNITY Screen, is a non-invasive prenatal test that uniquely assesses fetal risk for recessive conditions and chromosomal abnormalities from maternal blood. We are expanding this technology into liquid biopsy tests for cancer, aiming to transform how oncology care detects and monitors disease.

Where do you live now, and where would the company be based after YC?

We currently live and work in Menlo Park, CA, and would keep the company based there after YC.

Explain your decision regarding location.

We are based in Menlo Park because it provides access to top scientific talent and proximity to leading healthcare and biotech partners, which is critical for developing and refining our complex diagnostics technology.

21 respostas a mais na inscrição completa

Founders, Progress, Idea, Equity, Curious, Batch Preference estão na versão completa. Crie uma conta gratuita para abri-la no YC Insights, ao lado de todos os outros batches da YC.

Ver inscrição completa

Perguntas Frequentes

Esta é a inscrição real da YC de BillionToOne?

Não. A Y Combinator mantém as inscrições submetidas em privado. Esta é uma reconstrução: as perguntas reais do formulário da YC, respondidas a partir dos dados públicos de BillionToOne (notas de lançamento, históricos de fundadores, descrição do produto). Mostra como uma empresa como BillionToOne se apresentaria à YC, não o texto que eles submeteram.

Em qual batch da YC BillionToOne esteve?

BillionToOne fez parte do batch Summer 2017 da Y Combinator.

Quem fundou o BillionToOne?

O BillionToOne foi fundado por Oguzhan Atay, David Tsao.

O que o BillionToOne faz?

The genetic testing platform detecting and measuring disease.

Como eu leio o application completo reconstruído?

Crie uma conta gratuita no Round Funded. A versão completa de 26 respostas do application do BillionToOne, e de todos os outros lotes do YC, está no YC Insights.